Albireo Competitors

Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Albireo Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Albireo Pharma in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
16.1120.8425.57
Details
Intrinsic
Valuation
LowReal ValueHigh
19.3134.8839.61
Details
Naive
Forecast
LowNext ValueHigh
15.9820.7025.43
Details
5 Analysts
Consensus
LowTarget PriceHigh
67.0075.8084.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Albireo Pharma. Your research has to be compared to or analyzed against Albireo Pharma's peers to derive any actionable benefits. When done correctly, Albireo Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Albireo Pharma.

Albireo Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Albireo Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Albireo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Albireo Pharma does not affect the price movement of the other competitor.

Related Correlations

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

Nowadays, there is a big difference between Albireo Stock performing well and Albireo Pharma company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Albireo Pharma's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
TWTR 1.73  0.51  0.19 (1.52)  1.73  0.13 (1.84)  3.56 (2.97)  27.10 
MSFT 1.80 (0.11)  0.00 (0.03)  0.00 (0.0369)  0.00  3.92 (3.54)  11.64 
UBER 2.87 (0.21)  0.00 (0.09)  0.00 (0.0469)  0.00  8.60 (5.58)  19.67 
F 1.99 (0.28)  0.00 (0.14)  0.00 (0.09)  0.00  2.75 (5.20)  14.63 
T 1.28  0.18  0.12  0.31  1.09  0.09 (1.49)  2.54 (2.10)  9.29 
A 1.75  0.21  0.12  0.22  1.66  0.1 (2.15)  3.98 (2.97)  11.04 
CRM 2.41 (0.29)  0.00 (0.14)  0.00 (0.09)  0.00  4.31 (4.55)  18.29 
JPM 1.51  0.17  0.10  0.21  1.40  0.09 (1.65)  4.20 (2.80)  8.36 
MRK 0.99  0.36  0.27  1.20  0.81  0.25 (1.20)  2.44 (1.43)  7.38 
XOM 1.59  0.13  0.06  0.19  1.87  0.06 (1.65)  3.65 (2.91)  9.75 

Albireo Pharma Competitive Analysis

The better you understand Albireo Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Albireo Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Albireo Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALBO
 2.59 
 21.45 
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Cash Flow from Operations
Retained Earnings
Current Asset
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Total Asset
Short Ratio
Target Price
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Albireo Pharma Competition Performance Charts

Complement your Albireo Pharma position

In addition to having Albireo Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Munis Thematic Idea Now

Munis
Munis Theme
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Albireo Pharma Correlation with its peers. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
454.6 M
Quarterly Revenue Growth YOY
1.683
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ALBO
 Stock
  

USD 21.45  0.57  2.59%   

Analyzing Albireo Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Albireo Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Albireo Pharma competition on your existing holdings. Please continue to Albireo Pharma Correlation with its peers.
  
The value of Return on Investment is estimated to slide to -70.78. The value of Return on Average Assets is estimated to slide to -12.5. Albireo Pharma Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 85.25. Tangible Assets Book Value per Share is expected to rise to 15.21 this year, although the value of Goodwill and Intangible Assets will most likely fall to about 16.5 M.